Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is focused on the development
of potentially life-changing technologies for cancer patients. A recent article
discussing GNPX reads, “Genprex holds a portfolio of 30 issued and two pending
patents covering its technologies and targeted molecular therapies. The
company’s research and development program is focused on identifying and
developing leading-edge gene therapies that can be used alone or in combination
with other therapies for treatment of cancer. . . . Genprex’s initial product
candidate is Oncoprex, an immunogene therapy for the treatment of non-small
cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling
pathways that cause replication and proliferation of cancer cells,
re-establishes pathways for apoptosis (or programmed cell death) in cancer
cells and modulates the immune response against cancer cells. Oncoprex has also
been shown to block mechanisms that create drug resistance.”
To view the full article, visit http://ibn.fm/gXnvu
About Genprex Inc.
Genprex Inc. is a clinical-stage, gene-therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung
cancer (NSCLC). Genprex’s platform technologies are designed to administer
cancer-fighting genes by encapsulating them into nanoscale, hollow spheres
called nanovesicles, which are then administered intravenously and taken up by
tumor cells where they express proteins that are missing or found in low
quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of cancer
cells, re-establishes pathways for apoptosis, or programmed cell death, in
cancer cells and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug resistance. For more
information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks
are designed to keep investors up to date on important and breaking news in the
small-cap and micro-cap markets. Spanning all industries, including energy,
entertainment, telecommunications, healthcare, retail and more, these news breaks
deliver opportunities the investment community may have missed. Whether it is
earnings results, mergers and acquisitions, or any other market-moving news,
our news breaks keep you in the know. QualityStocks is committed to connecting
subscribers with companies that have huge potential to succeed in the short and
long-term future. It is part of our mission statement to help the investment
community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment